Manager TitleAgeSince
President - 30/07/2025
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/22 A Issuer sale

Chief Technology Officer

280,373 0.1193%
3/29/22 A Tax

Executive/Senior Manager

68,414 0.0293%
3/29/22 A Tax

Controller/Auditor

965 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.8B
+3.19%+8.48%+74.25%+153.03% 1,224B
-0.73%+2.09%+46.41%+87.64% 662B
+1.41%+3.40%+30.98%+112.26% 514B
+0.42%+2.88%+54.92%+69.67% 388B
+2.18%+1.55%+72.70%+45.42% 361B
+1.12%+3.80%+35.82%+59.72% 302B
+6.96%+7.55%+11.15%+37.89% 271B
+1.15%+4.19%+59.72%+78.16% 249B
+3.06%+8.58%+44.03%+122.76% 205B
Average +1.92%+2.59%+47.77%+85.17% 464.09B
Weighted average by Cap. +2.04%+3.04%+53.35%+100.42%
Logo Endo International plc
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116